Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386346 · ClinicalTrials.gov registry record · Phase 1
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
A Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01386346 is a Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01386346, a Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Azacitidine
- DRUG Epirubicin
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386346
The ClinicalTrials.gov registry entry for NCT01386346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT01386346 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01386346 about?
NCT01386346 is a clinical study titled "Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer". The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
What is the current status of trial NCT01386346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-06. Estimated completion is 2018-09.
What conditions does trial NCT01386346 study?
This clinical trial studies the following conditions: Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach.
What interventions are being tested in trial NCT01386346?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Azacitidine (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT01386346?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01386346 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Esophageal Cancer
All registered trials for this condition
Malignant Neoplasm of Cardio-esophageal Junction of Stomach
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.